Newamsterdam Pharma Company N.V. (NAMS)

$36.17 +0.59 (1.66%)
Market Cap 4.03B
Revenue (ttm) 45.56M
Net Income (ttm) -241.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -530.29%
Debt to Equity Ratio 0.00
Volume 796,500
Avg Vol 747,012
Day's Range N/A - N/A
Shares Out 113.39M
Stochastic %K 66%
Beta 0.06
Analysts Strong Sell
Price Target $49.00

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewA...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 35 206 2971
Address:
Gooimeer 2-35, Naarden, Netherlands
BlackForge
BlackForge Feb. 22 at 12:48 AM
$NAMS is developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in high‑risk cardiovascular patients a potential blockbuster class if approved…
0 · Reply
riskalex
riskalex Feb. 20 at 3:53 PM
$NAMS New Amsterdam Acquisition is a SPAC with dormant valuation. Capital preservation is the base case absent a merger. Upside depends on deal quality.
0 · Reply
erevnon
erevnon Feb. 18 at 7:10 PM
Needham maintains NewAmsterdam Pharma Co $NAMS at Buy and raises the price target from $46 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 18 at 2:11 PM
$NAMS mace rates tracking well so far in prevail trial.
0 · Reply
masonat
masonat Feb. 18 at 1:02 PM
$NAMS Based on this it seems we can expect the alzheimer's study to be: - APOE4 carriers/homozygotes - elevated pTau-217 (guessing >0.42) - no cognitive impairment This will hopefully be early enough to see treatment effect but not so early that the trial needs to run five+ years just to see enough cognitive decline for the study to be sufficiently powered.
0 · Reply
masonat
masonat Feb. 17 at 3:42 PM
$NAMS Good read on why obicetrapib might be successful in Alzheimer's. https://www.sciencedirect.com/science/article/pii/S266666772600036X
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 1:21 PM
$NAMS RSI: 47.34, MACD: -0.0309 Vol: 1.26, MA20: 32.87, MA50: 34.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 10:09 PM
$NAMS RSI: 51.11, MACD: -0.6853 Vol: 1.23, MA20: 32.68, MA50: 34.78 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
masonat
masonat Feb. 5 at 2:19 AM
$NAMS MRK's oral PCSK9 looking solid. At this point you know what you're getting with PCSK9s. Guessing they didn't see any MACE signal despite a slightly larger trial than Obi's Broadway since they didn't say anything about it. https://www.nejm.org/doi/full/10.1056/NEJMoa2511002?query=featured_home&logout=true
0 · Reply
PhoenixFlow
PhoenixFlow Feb. 4 at 9:12 AM
$NAMS Nordic financials, interest margin expansion
0 · Reply
Latest News on NAMS
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

Feb 18, 2026, 7:00 AM EST - 5 days ago

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 6, 2026, 4:01 PM EST - 17 days ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

Feb 4, 2026, 8:00 AM EST - 19 days ago

NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

Jan 9, 2026, 8:00 AM EST - 6 weeks ago

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 6:33 PM EST - 2 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

Nov 25, 2025, 8:00 AM EST - 3 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

Nov 16, 2025, 10:30 AM EST - 3 months ago

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Nov 5, 2025, 8:00 AM EST - 3 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Oct 30, 2025, 8:00 AM EDT - 4 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 24, 2025, 8:00 AM EDT - 5 months ago

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 10:22 PM EDT - 6 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Aug 25, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 21, 2025, 2:41 AM EDT - 6 months ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 18, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Aug 6, 2025, 7:00 AM EDT - 7 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 30, 2025, 8:25 AM EDT - 7 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 7 months ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 9, 2025, 7:00 AM EDT - 9 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

Jun 5, 2025, 8:00 AM EDT - 9 months ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 27, 2025, 8:00 AM EDT - 9 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 8, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 7, 2025, 7:15 AM EDT - 10 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Apr 30, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 8:00 AM EDT - 11 months ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 11:26 PM EST - 1 year ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 28, 2025, 10:48 AM EST - 1 year ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 26, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Feb 25, 2025, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 5:16 PM EST - 1 year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 9:37 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 1:33 PM EST - 1 year ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 4:34 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 11:14 AM EST - 1 year ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Dec 10, 2024, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Oct 4, 2024, 12:09 PM EDT - 1 year ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 30, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Aug 28, 2024, 1:33 PM EDT - 1 year ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 9, 2024, 8:00 AM EDT - 2 years ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Apr 1, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 25, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Mar 12, 2024, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 28, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 10:40 PM EST - 2 years ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

BlackForge
BlackForge Feb. 22 at 12:48 AM
$NAMS is developing obicetrapib, an oral CETP inhibitor for lowering LDL cholesterol in high‑risk cardiovascular patients a potential blockbuster class if approved…
0 · Reply
riskalex
riskalex Feb. 20 at 3:53 PM
$NAMS New Amsterdam Acquisition is a SPAC with dormant valuation. Capital preservation is the base case absent a merger. Upside depends on deal quality.
0 · Reply
erevnon
erevnon Feb. 18 at 7:10 PM
Needham maintains NewAmsterdam Pharma Co $NAMS at Buy and raises the price target from $46 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
outlawinvestor1
outlawinvestor1 Feb. 18 at 2:11 PM
$NAMS mace rates tracking well so far in prevail trial.
0 · Reply
masonat
masonat Feb. 18 at 1:02 PM
$NAMS Based on this it seems we can expect the alzheimer's study to be: - APOE4 carriers/homozygotes - elevated pTau-217 (guessing >0.42) - no cognitive impairment This will hopefully be early enough to see treatment effect but not so early that the trial needs to run five+ years just to see enough cognitive decline for the study to be sufficiently powered.
0 · Reply
masonat
masonat Feb. 17 at 3:42 PM
$NAMS Good read on why obicetrapib might be successful in Alzheimer's. https://www.sciencedirect.com/science/article/pii/S266666772600036X
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 1:21 PM
$NAMS RSI: 47.34, MACD: -0.0309 Vol: 1.26, MA20: 32.87, MA50: 34.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 5 at 10:09 PM
$NAMS RSI: 51.11, MACD: -0.6853 Vol: 1.23, MA20: 32.68, MA50: 34.78 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
masonat
masonat Feb. 5 at 2:19 AM
$NAMS MRK's oral PCSK9 looking solid. At this point you know what you're getting with PCSK9s. Guessing they didn't see any MACE signal despite a slightly larger trial than Obi's Broadway since they didn't say anything about it. https://www.nejm.org/doi/full/10.1056/NEJMoa2511002?query=featured_home&logout=true
0 · Reply
PhoenixFlow
PhoenixFlow Feb. 4 at 9:12 AM
$NAMS Nordic financials, interest margin expansion
0 · Reply
masonat
masonat Jan. 30 at 4:42 PM
$NAMS Get this down in the 20s and I might buy back the shares that I trimmed.
0 · Reply
newfguy
newfguy Jan. 9 at 3:12 PM
$NAMS https://ir.newamsterdampharma.com/news-releases/news-release-details/newamsterdam-pharma-highlights-2025-achievements-and-outlines
0 · Reply
Tip1
Tip1 Jan. 8 at 1:58 AM
$NAMS https://www.sciencedirect.com/science/article/pii/S227458072500336X “These findings represent the first demonstration of an oral intervention capable of reducing both beta-amyloid and tau pathology biomarkers in ApoE4 carriers, offering a potential preventive strategy for this high-risk population who currently have no effective prevention options.“
0 · Reply
GeologistG
GeologistG Dec. 25 at 11:23 AM
$NAMS The next leg of valuation movement will likely hinge on how management navigates competing priorities. Resource allocation will signal whether leadership prioritizes endurance or speed. Successful iteration can create optionality that is not yet fully priced. Investors will likely wait for pattern recognition before re‑committing capital.
0 · Reply
Petey3163
Petey3163 Dec. 19 at 10:55 PM
$ESPR we have amazing news and $NAMS has a better day? 😂
1 · Reply
newfguy
newfguy Dec. 19 at 5:58 PM
$NAMS buy all weakness
0 · Reply
Albertowest
Albertowest Dec. 18 at 11:03 AM
$NAMS beware of the final rug pull
0 · Reply
JarvisFlow
JarvisFlow Dec. 16 at 5:29 PM
Stifel has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 44 → 50.
0 · Reply
LuckyGuy9
LuckyGuy9 Dec. 12 at 11:09 PM
$NAMS Brand new here and I’m very interested in learning more about this company. Any resident bulls I need to read up on? I wanna know what’s a good entry, future catalysts, and what’s a reasonable timeline for an exit. Also what are the possible downsides the community might be concerned with
1 · Reply
newfguy
newfguy Dec. 10 at 6:25 PM
$NAMS MAA submission to EMA was August 18, expected approval for EU market July to September 2026
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 9 at 11:07 PM
$NAMS Current Stock Price: $34.80 Contracts to trade: $35 NAMS Dec 19 2025 Call Entry: $0.20 Exit: $0.36 ROI: 82% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
CaptainAmrica
CaptainAmrica Dec. 9 at 2:33 PM
$NAMS... Its been a good trade.
1 · Reply